In the last few years, a number of promising drugs that treat serious conditions and diseases have come through drugmakers’ pipelines. Recent developments in oncology, for instance, mean that there are more promising, potential blockbuster cancer drugs undergoing clinical trials than perhaps ever before. Many of these drugs have been issued breakthrough therapy designations from the FDA, or have been approved for the “fast track” to approval by the agency. Further, it’s estimated that as many as 76 new drugs could be launched worldwide this year, a cohort capable of generating as much as $23 billion by 2019, Barron’s notes.
Hey, check out all the research scientist jobs. Post your resume today!
